Jefferies Group LLC reissued their buy rating on shares of FibroGen, Inc (NASDAQ:FGEN) in a research note published on Tuesday morning. Jefferies Group LLC currently has a $75.00 target price on the biopharmaceutical company’s stock.
FGEN has been the subject of a number of other research reports. Leerink Swann reissued an outperform rating and set a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair reissued an outperform rating on shares of FibroGen in a research note on Wednesday, August 9th. Citigroup Inc. boosted their target price on shares of FibroGen from $48.00 to $65.00 and gave the stock a top pick rating in a research note on Tuesday, August 8th. BidaskClub cut shares of FibroGen from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Finally, Stifel Nicolaus reissued a buy rating and set a $38.00 target price (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $60.17.
FibroGen (NASDAQ:FGEN) opened at 52.40 on Tuesday. The stock’s 50 day moving average price is $43.31 and its 200-day moving average price is $32.07. The stock’s market cap is $3.73 billion. FibroGen has a 12 month low of $15.60 and a 12 month high of $52.70.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts expect that FibroGen will post ($1.80) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “FibroGen, Inc (FGEN) Earns “Buy” Rating from Jefferies Group LLC” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/16/fibrogen-inc-fgen-earns-buy-rating-from-jefferies-group-llc.html.
In other news, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $51.29, for a total transaction of $969,381.00. Following the completion of the sale, the chief executive officer now owns 3,297,655 shares of the company’s stock, valued at $169,136,724.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rory B. Riggs sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $51.92, for a total transaction of $1,298,000.00. Following the sale, the director now directly owns 435,200 shares of the company’s stock, valued at approximately $22,595,584. The disclosure for this sale can be found here. Insiders have sold 509,328 shares of company stock valued at $21,719,918 in the last three months. Corporate insiders own 14.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. purchased a new stake in FibroGen during the 1st quarter valued at about $111,000. Quantbot Technologies LP purchased a new stake in FibroGen during the 2nd quarter valued at about $128,000. SG Americas Securities LLC grew its stake in FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 412 shares in the last quarter. Airain ltd purchased a new stake in FibroGen during the 1st quarter valued at about $236,000. Finally, Amalgamated Bank purchased a new stake in FibroGen during the 2nd quarter valued at about $237,000. 47.49% of the stock is owned by institutional investors.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.